Poolbeg Pharma is very pleased to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myeloma. As an oral preventative therapy for CRS, POLB 001

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release

Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application. This AIM-traded firm said the development

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a

February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for

As the global obesity epidemic continues to escalate, the development of effective obesity management solutions has become a front and centre topic in the life sciences sector. With over 650

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024. The

U.K.-based Poolbeg Pharma is taking a different approach with its POLB 001, a small molecule immunomodulator that has already shown promise in a lipopolysaccharide (LPS) human challenge trial. A human challenge